Abstract p53, which is encoded by the most frequently mutated gene in cancer, TP53, is an
attractive target for novel cancer therapies. Despite major challenges associated with this …

Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) originate from
preleukemic hematopoietic conditions, such as clonal hematopoiesis of indeterminate …

Regulated cell death (RCD) is a controlled form of cell death orchestrated by one or more
cascading signaling pathways, making it amenable to pharmacological intervention. RCD …

The mutational landscape of TP53, a tumor suppressor mutated in about half of all cancers,
includes over 2,000 known missense mutations. To fully leverage TP53 mutation status for …

Haematological malignancies are heterogeneous groups of cancers of the bone marrow,
blood or lymph nodes, and while therapeutic advances have greatly improved the lifespan …

The tumour suppressor gene p53 is one of the most frequently mutated genes in lung cancer
and these defects are associated with poor prognosis, albeit some debate exists in the lung …

Diabetic foot ulcer, is a chronic complication afflicting individuals with diabetes, continue to
increase worldwide, immensely burdening society. Programmed cell death, which includes …

Pancreatic cancer (PC) is one of the deadliest malignancies; p53 is mutated in
approximately 75% of PC patients. Hence, the protein derived from mutant/wild-type TP53 …

Next-generation sequencing of samples from patients with acute myeloid leukemia (AML)
has revealed several driver gene mutations in adult AML. However, unlike other cancers …

Objective New prognostic biomarkers, and bio-signatures, are urgently needed to facilitate a
precision medicine-based approach to more effectively treat patients with high-grade serous …